RESUMEN
Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantages for therapy of de novo and relapsed NHL.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma no Hodgkin/tratamiento farmacológico , Adulto , Anciano , Bleomicina/administración & dosificación , Bleomicina/efectos adversos , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Doxorrubicina/administración & dosificación , Doxorrubicina/efectos adversos , Femenino , Humanos , Leucovorina/administración & dosificación , Leucovorina/efectos adversos , Linfoma no Hodgkin/mortalidad , Masculino , Metotrexato/administración & dosificación , Metotrexato/efectos adversos , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Prednisona/administración & dosificación , Prednisona/efectos adversos , Vincristina/administración & dosificación , Vincristina/efectos adversosRESUMEN
Chronical course, splenomegaly and pancytopenia are characteristic for hairy cell leukemia. The main feature are so-called hairy cells in peripheral blood. This cells were investigated by cytological, cytochemical, histological and electron microscopical methods. Special cytoplasmic inculsions seem to be specific for this cell type.
Asunto(s)
Leucemia/sangre , Adulto , Médula Ósea/ultraestructura , Citoplasma/ultraestructura , Gránulos Citoplasmáticos/ultraestructura , Humanos , Técnicas In Vitro , Leucemia/patología , Enfermedades Linfáticas/sangre , Enfermedades Linfáticas/patología , Linfocitos/metabolismo , Masculino , Mitocondrias/ultraestructura , Monocitos/metabolismo , Ribosomas/ultraestructura , EsplenomegaliaRESUMEN
Some cases of hemoblastosis with CNS-involvement were investigated by methods of light microscopy, cytochemistry and electronmicroscopy. The unique cell picture, as observed by light microscopy could not be proven by electronmicroscopic results. This fact was supported by comparative investigations of inflammation processes. Typical structures are described and discusses.